- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
OrganiGram Holdings announced the launch of a new premium line of cannabis products called the Edison Project.
OrganiGram Holdings (TSXV:OGI; OTCQB:OGRMF) announced the launch of a new premium line of cannabis products called the Edison Project.
As quoted in the press release:
The Edison Project is an initiative designed to produce and offer OrganiGram patients the very highest quality flower possible using the latest in technology and industry best practices.
“The Edison Project represents our very best work to date,” says Ray Gracewood, OrganiGram’s Chief Commercial Officer. “We’re most proud of these strains of medicine because they’re a product of our intensive research on the biology of cannabis and continuous improvement in production. We’ve adopted a culture of refusing to settle at Organigram; it’s evolved such that we’ve come to discover more about the true potential in our plants and we’ve learned how to deliver the benefit of that potential to our patients.”
Click here to read the full press release.
Source: www.newswire.ca
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.